Johnson & Johnson $JNJ Shares Sold by Anchor Capital Advisors LLC

Anchor Capital Advisors LLC lessened its stake in Johnson & Johnson (NYSE:JNJ) by 2.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,525 shares of the company’s stock after selling 3,111 shares during the period. Anchor Capital Advisors LLC’s holdings in Johnson & Johnson were worth $30,737,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also made changes to their positions in JNJ. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after buying an additional 3,731,074 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Johnson & Johnson by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock worth $11,967,947,000 after purchasing an additional 1,738,292 shares in the last quarter. Norges Bank acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $6,924,523,000. Wellington Management Group LLP boosted its position in Johnson & Johnson by 3.8% during the third quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company’s stock worth $4,789,914,000 after acquiring an additional 956,239 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in Johnson & Johnson by 2.8% during the third quarter. Legal & General Group Plc now owns 19,450,064 shares of the company’s stock worth $3,606,431,000 after acquiring an additional 532,790 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: CNBC’s Jim Cramer pointed to Johnson & Johnson as one of five stocks to buy for diversification outside the AI trade, which could attract investors looking for lower-volatility, defensive exposure. Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification
• Positive Sentiment: Scotiabank reiterated its Buy rating on Johnson & Johnson, reinforcing Wall Street confidence in the company’s earnings durability and dividend appeal. Scotiabank Sticks to Their Buy Rating for Johnson & Johnson (JNJ)
• Positive Sentiment: Several articles highlighted JNJ as one of the best dividend-paying stocks to own, which can support the stock as investors favor income and defensive healthcare names. Is Johnson & Johnson (JNJ) One of the Best Dividend Paying Stocks to Buy Right Now?
• Neutral Sentiment: Recent commentary also questioned whether Johnson & Johnson’s strong one-year rally leaves limited upside near current levels, suggesting valuation could temper enthusiasm. Is It Too Late To Consider Johnson & Johnson (JNJ) After Its 48% One-Year Surge?
• Neutral Sentiment: A Motley Fool piece argued JNJ’s effort to challenge AbbVie’s growth driver should not alarm AbbVie shareholders, implying the competitive angle is not a major near-term negative for Johnson & Johnson itself. Johnson & Johnson Hopes to Dethrone AbbVie’s Biggest Growth Driver. Here’s Why Investors Shouldn’t Panic

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $223.00 on Wednesday. The firm’s fifty day moving average price is $232.75 and its 200 day moving average price is $225.29. The company has a market capitalization of $536.81 billion, a price-to-earnings ratio of 25.78, a price-to-earnings-growth ratio of 2.19 and a beta of 0.26. Johnson & Johnson has a 12-month low of $149.04 and a 12-month high of $251.71. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company’s revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, research analysts forecast that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a $1.34 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.97%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on JNJ shares. Guggenheim lifted their price target on shares of Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a report on Monday, April 20th. TD Cowen initiated coverage on shares of Johnson & Johnson in a report on Wednesday, April 8th. They set a “buy” rating and a $250.00 target price on the stock. Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a report on Wednesday, April 15th. JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Finally, Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $253.04.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.